鈉葡萄糖轉運蛋白（SGLTs）抑制之抗纖維化活性：於糖尿病心肌病變治療的潛力

Medicine & Life Sciences

1. Cardiomyopathies 100%
2. Diabetes Mellitus 99%
3. 3-(3-(4-(3-(glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl)-3-methylphenoxy)propylamino)propionamide 82%
4. empagliflozin 70%
5. (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 69%
6. Fibrosis 59%
7. Sodium-Glucose Transporter 2 Inhibitors 49%
8. Type 2 Diabetes Mellitus 42%
9. Fibroblasts 42%
10. Symporters 31%
11. N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine 21%
12. High-Throughput Nucleotide Sequencing 21%
13. MicroRNAs 19%
14. C.I. direct red 80 17%
15. Collagen 17%
16. Sodium-Glucose Transport Proteins 16%
17. Atrial Remodeling 15%
18. Western Blotting 15%
19. Immunochemistry 15%
20. Egtazic Acid 13%
21. NG-Nitroarginine Methyl Ester 13%
22. Chelating Agents 12%
23. Optical Imaging 12%
24. Mortality 11%
25. Autophagy 10%
26. Action Potentials 10%
27. Echocardiography 9%
28. Sodium 9%
29. Rodentia 9%
30. Wistar Rats 9%
31. Electrocardiography 9%
32. Nitric Oxide 9%
33. Reactive Oxygen Species 9%
34. Oxidative Stress 8%
35. Homeostasis 8%
36. Calcium 7%
37. Heart 7%
38. Staining and Labeling 7%
39. Glucose 7%
40. Cytokines 7%
41. Apoptosis 6%
42. Control Groups 6%